Market Research Logo

Biotherapeutics: Novel Formulation and Delivery Approaches Focus on Antibodies and Proteins 2015 - 2025

Biotherapeutics: Novel Formulation and Delivery Approaches Focus on Antibodies and Proteins 2015 - 2025

Biopharmaceuticals is currently one of the fastest growing segments in the pharmaceutical industry. They have a vital use in the treatment of chronic diseases and also result in high profit margins for the drug developers. There are several therapeutic areas for which biopharmaceuticals are being investigated; these include oncology, metabolic disorders, viral infections, genetic disorders and immunological disorders. Biotherapeutics (both approved and under investigation) include monoclonal antibodies, cell therapies, clotting factors, cytokines, enzymes, hormones and vaccines. In fact, several antibody based therapies have already been approved across the globe. Humira®, by AbbVie, is a well-known example; the drug has been generating multibillion dollar sales annually for several years.

The major challenge for biologics has been the mode of administration. For most large molecule drugs, IV is an established route. Through this method, the drug directly enters systemic circulation bypassing degradation in the gastrointestinal (GI) tract. However, there are other challenges; these include the requirement of healthcare experts for drug administration (in turn, increasing the cost of therapy) and associated pain during therapy administration (negatively impacting patient compliance).Companies developing biologics are continuously on the lookout for novel formulation and delivery systems in order to exploit their full therapeutic and commercial potential. Amongst the various aspects being studied, technologies for facilitating oral, subcutaneous (SC) and transdermal delivery of biologics are highly sought after and have received widespread attention from researchers and manufacturers across the globe.

Several start-ups, with innovative technologies, have surfaced in the past decade and have continuously encouraged the use of biotherapeutics by providing novel approaches to improve patient compliance. These technologies are broadly classified either as formulation technologies (approaches with primary objective of changing the formulation of drug, thereby facilitating an alternate route of administration in many cases) or delivery systems (approaches with primary objective of developing a physical system to deliver the drug via an alternate route).

The overall interest continues to rise as is evident from the number of partnerships / agreements that have taken place amongst the stakeholders. Technology licensing agreements have been very common and are likely to play an active role in industry’s development. In addition, several venture capitalists have led multiple funding rounds in these companies, acting as a key enabler behind the evolution.

SCOPE OF THE REPORT
The ‘Biotherapeutics: Novel Formulation and Delivery Approaches (Focus on Antibodies and Proteins)’report provides a comprehensive analysis of the current market landscape and the future outlook of technologies focused on the formulation and delivery of biotherapeutics, primarily proteins and antibodies. Biopharmaceuticals has become an area of heavy interest for many pharmaceutical companies; they make up about one-third of all the drugs that are currently in development. The industry is growing at a healthy pace resulting in a substantial shift from conventional chemical synthesis to biotechnological processes in the way drugs are now produced.

Intravenous (IV) route has been the most popular route for administering large molecule drugs such as proteins and antibodies. However, with the rising popularity of biologics and biosimilars, several companies are now looking forward to technologies that can be used for delivering biotherapeutics via a route other than IV injection or infusion. Technologies focused on oral, SC and transdermal routes are becoming more popular and, therefore, are expected to be the major contributors to the overall drug delivery technologies market. In addition, there are other novel targeted approaches, such as bypassing blood brain barrier, which are likely to change the industry paradigm in the long run.

During the course of our research, we identified 122 such companies that are developing either formulation technologies or novel systems for delivery of large molecule drugs. The study not only provides the list of technologies but also includes a detailed analysis on the overall market for these technologies. We have looked at the investments that have been made into these technologies and have provided detailed information of the various collaborations / licensing agreements amongst the stakeholders. This advancing trend of transition from IV to alternate delivery mechanisms highlights the crucial role of technology developers in this field.

The base year for the report is 2015. The report provides the market forecast for the period 2015-2025. The research, analysis and insights presented in this report are backed by a deep understanding,developed from both primary and secondary research, of key drivers behind the growth.

EXAMPLE HIGHLIGHTS
There are over 150 technologies, being developed by around 120 companies, which are focused on developing novel formulations and / or systems for delivering antibodies and proteins. Amongst the delivery systems, prime focus of the stakeholders is on oral, SC and transdermal drug delivery technologies.

The market has attracted several start-ups; these companies, in collaboration with big pharma, are expected to foster more innovation in the near future. Some of the well-known players with proprietary technologies are (in alphabetical order) Adocia, Aegis Therapeutics, Arecor, Corium International, Cosmo Pharmaceuticals, Durect Corporation, Emisphere Technologies, Excelse Bio, Generex Biotechnology, Halozyme Therapeutics, Merrion Pharmaceuticals, Oramed Pharmaceuticals, Rani Therapeutics, Xeris Pharmaceuticals and Zosano Pharma (complete list in Chapter 4 of the report).

These approaches focus on a wide range of mechanisms; amongst others, these include modifying the release properties along with pharmacokinetic properties, creating cold-chain free and stable liquid formulations of the drug and delivering the drugs in a targeted manner.

Within the technologies focused on targeted delivery, there seems to be heavy focus on delivery of drugs across the Blood Brain Barrier (BBB). Delivery across the BBB has been a big challenge in case of large sized biologics. We have identified over 15 players, which aim to successfully overcome this challenge in the coming few years.

Venture capitalists have shown an enormous amount of interest and confidence in the technology developers. In total, we traced over 200 instances of funding with the total investment amounting to an encouraging sum of USD 2.9 billion over the last decade. In addition, government agencies, such as the NIH, have also encouraged technology developers by issuing grants for a wide range of research projects.

Driven by several factors, such as rising incidence of chronic diseases, growing popularity of biologics / biosimilars and use of delivery / formulation technologies as life cycle management tools for near patent expiry drugs, the market for such technologies is expected to grow aggressively at a healthy annual growth rate of 9.6% between 2015 and 2025.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our study. The summary offers a high level view on the likely market evolution of the drug delivery technologies for biotherapeutics.

Chapter 3 is an introductory chapter on biotherapeutics. It includes the various advantages and challenges faced by technology developers in developing systems for delivering biotherapeutics. We have also presented, in detail, a discussion on the approved antibody therapeuticsin the market, signifying the growing trend towards alternate delivery mechanisms.

Chapter 4 identifies the various approaches / technologies / systems that can be used to formulate and administer biologics. The classification system for the technologies mentioned in this chapter helps develop a deeper understanding of the market.

Chapter 5 reviewsthe key technologies available for oral delivery of biotherapeutics. We have presented profiles of several leading technologies covering information on their origin, mechanism, molecules based on these technologies and associated companies.

Chapter 6 includes profiles of key technology developers specialising in formulating and delivering biotherapeutics via the SC route. Each profile includes information such as technology overview, pipeline review, funding details and recent developments.

Chapter 7reviews the major technologies available for transdermal/intradermal administration of biotherapeutics. Several leading companies, along with their technologies, have been profiled in this chapter. As in earlier chapters, these profiles provide an overview of the technology developers, mechanism of technologies, drugs in the pipeline based on specific technologies and associated recent developments.

Chapter 8 discusses technologies focused on other alternative administration routes (other than oral, SC and transdermal). The chapter includes key insights on technologies that alter the release kinetics and pharmacokinetics of the drug. In addition, certain technologies focused on targeted delivery, such as delivery across the blood-brain-barrier, have also been covered in this chapter.

Chapter 9 highlights the recent partnerships that have taken place in the industry. We have also discussed the various partnership models in existence and the most common forms of deals/agreements that have evolved over time.

Chapter 10provides information on several funding instances that have driven research and development of formulation and delivery technologies for biotherapeutics. Our analysis reveals interesting insights on the growing interest of venture capitalists and other stakeholders in this market.

Chapter 11 presents a detailed ten year forecast highlighting the potential for technology developers engaged in developing technologies for delivery of biotherapeutics. Due to the uncertainty surrounding some of the key assumptions, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios. Our insights are backed by discussions with several stakeholders in the industry.

Chapter 12 provides a SWOT analysis of the drug delivery technologies market for biotherapeutics, giving strategic insights to the major factors that are likely to drive future growth whilst highlighting the weaknesses and threats that may negatively impact the industry’s evolution.

Chapter 13 is a collection of transcripts of interviews conducted with key players during the course of this study.

Chapter 14 summarises the overall report. In this chapter, we provide a recap of the key takeaways and an independent future outlook based on the research and analysis described in earlier chapters.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides a list of companies and organisations mentioned in the report.

LIST OF COMPANIES AND ORGANISATIONS

Following companies have been mentioned in this report.
4P Therapeutics
AbbVie
ADOCIA
Advanced Accelerator Applications
Aegis Therapeutics
Aerogen
Affilogic
Affinity Therapeutics
Agila Specialities
AIMM Therapeutics
Albany Medical College
Alchemia
Alcyone
Allergan
Alrise Biosystems
Althea
Amarantus BioSciences
AmatsiSEPS
Angiochem
Aphios
Applied Molecular Transport
Apricus Biosciences
Aquarius Biotechnologies (Acquired by Matinas Biopharma)
Aradigm
Aratana Therapeutics
Arecor
ArmaGen
Arsenal Medical
Asahi Kasei Pharma
Ascendis Pharma
AstraZeneca
Axela Biosensors
Battelle
Baxter
Bayer Healthcare
biOasis Technologies
BioCardia
Biodel
BioLingus
BrainsGate
Caleva Process Solutions
Camarus AB
CannScience Innovations
Capsugel
Carbylan Therapeutics
Carlina Technologies
CarThera
Catalent Pharma
CellProThera
Chiasma Pharmaceuticals
Circassia Pharmaceuticals
Corium International
Cosmo Pharmaceuticals
CrossLink Bioscience
Cubist Pharmaceuticals
Dainippon Sumitomo
Delpor
DelSiTech
DNAtrix
DNX
Dr. Reddy's
Durect Corporation
Dynamic Microbials
Eisai
Ekteino
Elcam Medical
Eli Lilly
Emisphere
Encap
Endo International
Entrega Bio
ETI Karle Clinical
ExcelseBio
Extend Biotechnology
Ferring Pharmaceuticals
Flamel Technologies
FluGen
Galena Biopharma
GALVmed
GenBiotech
Genentech
Generex Biotechnology
Generium
Genta
Genzyme
Geron
GlaxoSmithKline
Graybug
GSK
H Lundbeck
Halozyme Therapeutics
Hikma Pharmaceuticals
Hospira
Hovione
ICB International
Innocore
Intarcia Therapeutics
Integrated Animal Health
Intranasal Technology Inc (ITI)
Intrexon
Janssen Pharmaceuticals
JCR Pharmaceuticals
Johnson and Johnson
JRX Biotechnology
Kaer Therapeutics
KemPharm
Kereos
Kurve Technology
Kytogenics Pharmaceuticals
Landec
Laser Detect Systems
Latitude Pharmaceuticals
Lauren Sciences
Le Métier de Beauté
Leukocare Biotechnology
Lipotek
Liquidia Technologies/ Envisia Therapeutics
Lung Rx
Lysogene
Medallion Therapeutics
Medicure
MedImmune
MedinCell
Medpace
Merck
Merrion Pharmaceuticals
Midatech Group
MIS Dental Implants Technologies
Monosol Rx
Mountain View Pharmaceuticals
MSD Animal Health
Mylan
Nano Precision Medical
Nanomerics
NanoPass Technologies
Nanovector
NeuroNano
Neurotech
NHTherapeutics
NOD Pharmaceuticals
Novartis
Novo Nordisk
Oakwood Laboratories
Octoplus
Ocular Therapeutix
Opsona Therapeutics
Oramed Pharmaceuticals
Orbis Biosciences
Orion Pharma
Pacira Pharmaceuticals
Pantec Biosolutions
PATH
Patheon
PCI Biotech
Pearl Therapeutics
Peptineo
Permeon Biologics
Pfizer
Pharmidex
PhaseBio Pharmaceuticals
Phosphagenics
Phylogica
PolyPid
ProCore Bio Med
ProLynx
Prometheon Pharma
Protheragen
Proxima Concepts
pSivida
Pulmatrix
Rani Therapeutics
Roche
Ruthigen
Sagetis Biotech
Sanofi
Sanofi Aventis
Santen
Scil Proteins
Serina Therapeutics
Servier
Shire
Smoofi
Solvanix
Stallergenes
Sterigenics
Strativa Pharmaceuticals
Suda
Swiss Caps AG
Symphony Medical
Synthelis
Takeda Pharmaceuticals
Tamarisk Technologies Group
Targeted Cell Therapies
TheraKine
Tibotec
Transdermal Corp.
Transdermal Specialties
UCB
UCL
Valerion Therapeutics
Valeritas
Vaxxas
Vect-Horus
Vectura
Vestiq Pharmaceuticals
Wacker Biotech
Wyeth Pharmaceuticals
Xenetic Biosciences
Xenios AG
Xeris Pharmaceuticals
XL Protein GmbH
XstalBio
YEDA
Zogenix
Zosano Pharma

Following VC Firms have been mentioned in the report
5AM Ventures
7 Med Health Ventures
Abingworth
Advanced Technology Ventures
Aegis Capital Corp
AGF Private Equity
Alpes Developpement Durable Investissement
Alpha Associates
Alta Partners
Altitude Life Sciences Ventures
AnGes MG
Apax Partners
Aphelion Capital
ARCH Venture Partners
Ascension Health Ventures
Astellas Venture Management
Atlas Venture
Avida Group
BDC Capital
Beacon Angels
Beta Fund
Bill & Melinda Gates Foundation
Bioam Gestion
BioMed Ventures
Boehringer Ingelheim Venture Fund
Boston Harbor Angels
Brandon Capital
Broadfin Capital
Burrill and Company
Business Development Bank of Canada
Canaan Partners
Capital Royalty
Capital Royalty Partners II
CDC Enterprises
Central Texas Angel Network
Chase H&Q
Cherrystone Angel Group
Chicago Growth Partners
CHL Medical Partners
Clarus Ventures
CNF Investments
Covington Capital
Crystal Horizon Investments
Deerfield Management
Deutsche Banc Alex. Brown
DNA Biomedical Solutions Ltd.
Domain Associates
DSM Venturing
Edward P. Bass group
Essex Woodlands Health Ventures
F2 Capital
F2 Ventures
F3 Ventures
Firelake Capital Management
Fletcher Spaght Ventures
Fredric Price
Glide Healthcare Partners
Golden Seeds
Google Ventures
Granite State Angels
Hambrecht & Quist
Harbor Light Capital Partners
Harkness & Hill
Hatteras Venture Partners
HBM BioVentures
Health Ventures
HealthCare Venture
Hercules Technology Growth Capital
HLM Venture Partners
Hygea VCT Plc
Idinvest Partners
InCube Ventures
InterSouth Partners
InterWest Partners
Investment Accelerator Fund-Life Sciences
Israel HealthCare Ventures
J&J Development Corporation
Jerusalem Global Ventures
Kaiser Permanante Ventures
Kingsbridge Capital
Ladenburg Thalmann & Co.
LaunchPad Venture Group
Life Science Angels
LifeCare Partners
Maryland Venture Fund
Mass Medical Angels
Maxim Group LLC
Mayflower
Medical Research Commercialisation Fund
Merlin Biosciences
MHR Funding Management
Mitsui & Co. Global Investment
Montaur Capital Partners
Morningside Group
MPM Capital
New Enterprise Associates
New Leaf Ventures
New River Management V
Nexus Medical Partners
Nomura International
Nomura Phase4 Ventures
North Bridge Venture Partners
North Country Angels
Northland Securities
Novartis Venture Fund
Ofer Hi-Tech
Omega Fund
OneVentures
ONSET Ventures
OrbiMed Advisors
OSI Pharmaceuticals
Oxford Finance
Oxford Finance Corporation
Pacific Venture Opportunity Fund
Pappas Ventures
Pharmsynthez
Pinemount Investment
Pitango Venture Capital
Polaris Partners
Polaris Venture Partners
Pound Capital
ProQuest Investments
Province of Nova Scotia
Quantum Technology Partners
RA Capital Management
Rhône-Alpes Création
Rock Springs Capital
Rodman & Renshaw, Ladenburg Thalmann & Co.
Savoy
Scale Venture Partners
SG Asset Management Private Equity
Siemens Venture Capital
Silicon Valley Bank
Sofinnova Partners
SofInnova Ventures
Sparta LLC
Sud Rhone-Alpes Capital
SV Life Sciences
Takeda Ventures
Tech Coast Angels
TechnoStart
Texas Venture Labs
The Halifax Group
The Stevanato Group
Think Equity Partners
Thomas McNerney & Partners
Vatera Healthcare Partners
Venrock
Venture Health
Versant Ventures
VG Partners
Viaduct
Viveris Management
Vivo Capital
Vivo Ventures
Wakefield Group
Warburg Dillon Read LLC, and Adams
WBB Securities
Welsh, Carson, Anderson & Stowe
Western Life Sciences Venture Fund
White Oak Global Advisors
WR Hambrecht + Co
Wuzhou Zhongheng Group
Xenia Ventures
Yissum Research Development

Following Institutes / Universities / Organisations have been mentioned in this report.
National Institute of Diabetes and Digestive and Kidney Disease
National Institute of Mental Health
National Institute of Standards and Technology
Bispebjerg University Hospital
Brigham and Women’s Hospital
Exeter University
Infectious Disease Research Institute
Laboratory for Drug Delivery (Georgia Institute of Technology)
The School of Pharmacy, University of London
Technical University Munich (TUM)
University of Cambridge


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. BIOPHARMACEUTICALS: AN INTRODUCTION
3.1. Background and Overview
3.2. Why Biopharmaceuticals are Gaining Attention?
3.3. Different Classes of Biotherapeutics
3.4. Biotherapeutics That Can Benefit From Drug Delivery Advances
3.4.1. Monoclonal Antibodies
3.4.2. Cell Therapies
3.4.3. Clotting Factors
3.4.4. Cytokines
3.4.5. Enzymes
3.4.6. Hormones
3.4.7. Vaccines
3.5. Antibody Therapies
3.5.1. Landscape of Approved Antibody Therapies
3.5.2. Approved Antibody Therapies: Distribution by Year of Approval
3.5.3. IV Infusion is the Most Common Route of Administration
3.5.4. Complexities and Complications Associated with the IV Route
3.6. Types of Drug Delivery Technologies
3.7. Demand for Novel Drug Delivery Technologies
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Delivery Technologies for Biotherapeutics (Proteins and Antibodies)
4.3. Most of the Technologies Focus on Novel Formulations
4.4. Major Proportion of the Technologies Focus on Specific Route of Administration
5. KEY ORAL FORMULATIONAND DELIVERY PLATFORMS
5.1. Chapter Overview
5.2. Technology Licensing is the Most Popular Partnership Model
5.3. Gastrointestinal Permeation Enhancement Technology (GIPET®, Merrion Pharmaceuticals)
5.3.1. Overview
5.3.2. Financial Information
5.3.3. Patents
5.3.5. Technology and Mechanism of Action
5.3.6. Advantages of the Technology
5.3.7. Pipeline Drugs Using GIPET®
5.3.8. Agreements / Collaborations
5.4. Protein Oral Delivery Technology (POD™, Oramed)
5.4.1. Overview
5.4.2. Financial Information
5.4.3. Patents
5.4.4. Technology and Mechanism of Action
5.4.5. Advantages of the Technology
5.4.6. Pipeline Drugs Using POD™
5.4.7. Agreements / Collaborations
5.5. Multi Matrix System (MMX®, Cosmo Pharmaceuticals)
5.5.1. Overview
5.5.2. Financial Information
5.5.3. Patents
5.5.4. Technology and Mechanism of Action
5.5.5. Advantages of the Technology
5.5.6. Pipeline Drugs Using MMX® Technology
5.5.7. Agreements / Collaborations
5.6. Eligen® (Emisphere Technologies)
5.6.1. Overview
5.6.2. Financial Information
5.6.3. In-house Development of Eligen
5.6.4. Technology and Mechanism of Action
5.6.5. Advantages of the Technology
5.6.6. Pipeline Drugs Using Eligen®
5.6.7. Agreements / Collaborations
5.7. RapidMist™ (Generex Biotechnology™)
5.7.1. Overview
5.7.2. Financial Performance
5.7.3. Technology and Mechanism of Action
5.7.4. Advantages of the Technology
5.7.5. Pipeline Drugs Using RapidMist™
5.7.6. Agreements / Collaborations
5.8. Axcess™ (Proxima Concepts)
5.8.1. Overview
5.8.2. Patents
5.8.3. Technology and Mechanism of Action
5.8.4. Advantages of the Technology
5.8.5. Pipeline Drugs Using Axcess™
5.8.6. Agreements / Collaborations
6. KEY SUBCUTANEOUS FORMULATION AND DELIVERY PLATFORMS
6.1. Chapter Overview
6.2. Technology Licensing and Research Collaboration are the Two Popular Partnership Models
6.3. ENHANZE™ Technology (Halozyme Therapeutics)
6.3.1. Overview
6.3.2. Financial Performance
6.3.3. Technology and Mechanism of Action
6.3.4. Advantages of the Technology
6.3.5. Pipeline Drugs Using ENHANZE™
6.3.6. Agreements / Collaborations
6.4. Bepo™ (MedinCell)
6.4.1. Overview
6.4.2. Patents
6.4.3. Technology and Mechanism of Action
6.4.4. Advantages of the Technology
6.4.5. Pipeline Drugs Using BEPO™
6.4.6. Agreements / Collaborations
6.5. Medusa™ (Flamel Technologies)
6.5.1. Overview
6.5.2. Financial Performance
6.5.3. Technology and Mechanism of Action
6.5.4. Advantages of the Technology
6.5.5. Pipeline Drugs Using Medusa™
6.5.6. Agreements / Collaborations
6.6. XeriJect™ (Xeris Pharmaceuticals)
6.6.1. Overview
6.6.2. Financial Information
6.6.3. Technology and Mechanism of Action
6.6.4. Advantages of the Technology
6.6.5. Pipeline Drugs Using XeriJect™
6.6.6. Agreements / Collaborations
6.7. BioChaperone® (Adocia)
6.7.1. Overview
6.7.2. Financial Performance
6.7.3. Technology and Mechanism of Action
6.7.4. Advantages of the Technology
6.7.5. Pipeline Drugs Using BioChaperone®
6.7.6. Agreements / Collaborations
6.8. Crystalomics® Technology (Ajinomoto Althea)
6.8.1. Overview
6.8.2. Financial Performance
6.8.3. Technology and Mechanism of Action
6.8.4. Advantages of the Technology
6.8.5. Pipeline Drugs Using Crystalomics®
6.8.6. Agreements / Collaborations
6.9. TransCon Technology (Ascendis Pharma)
6.9.1. Overview
6.9.2. Financial Information
6.9.3. Technology and Mechanism of Action
6.9.4. Advantages of the Technology
6.9.5. Pipeline Drugs Using TransCon
6.9.6. Agreements / Collaborations
7. KEY DERMAL FORMULATION AND DELIVERY PLATFORMS
7.1. Chapter Overview
7.2. Technology Licensing is the Most Common Agreement Model
7.3. MicroCor® Technology (Corium International)
7.3.1. Overview
7.3.2. Financial Performance
7.3.3. Patents
7.3.4. Technology and Mechanism of Action
7.3.5. Pipeline Drugs Using MicroCor®
7.3.6. Agreements / Collaborations
7.4. MicronJet (NanoPass Technologies)
7.4.1. Overview
7.4.2. Financial Information
7.4.3. Technology and Mechanism of Action
7.4.4. Pipeline Drugs Using MicronJet Needle
7.4.5. Agreements / Collaborations
7.5. ZP Patch Technology (Zosano Pharma™)
7.5.1. Overview
7.5.2. Financial Performance
7.5.3. Technology and Mechanism of Action
7.5.4. Pipeline Drugs Using ZP Patch
7.5.5. Agreements / Collaborations
8. OTHER FORMULATION AND DELIVERY PLATFORMS
8.1. Chapter Overview
8.2. Product Development and Evaluation Agreement are Preferred Modes of Collaboration
8.3. nanoZYME™, poloMAC™ and poxoMAC™ (NeuroNano Pharma)
8.3.1. Overview
8.3.2. nanoZYME™ Technology
8.3.3. poloMAC™ and poxoMAC™ Technologies
8.3.4. NeuroNano Pharma: Patent Portfolio
8.3.5. Agreements / Collaborations
8.4. ß-Eliminative Drug Delivery System (ProLynx)
8.4.1. Overview
8.4.2. Technology and Mechanism of Action
8.4.3. Advantages of the Technology
8.4.4. Patent Portfolio
8.4.5. Agreements / Collaborations
8.5. Intravail® and Aegis Hydrogels® (Aegis Therapeutics)
8.5.1. Overview
8.5.2. Intravail® Technology
8.5.3. Aegis Hydrogels® Technology
8.5.4. Agreements / Collaborations
8.6. PharmFilm® Technology (MonoSol Rx)
8.6.1. Overview
8.6.2. Financial Performance
8.6.3. Technology and Mechanism of Action
8.6.4. Advantages of the Technology
8.6.5. Pipeline Drugs Using PharmFilm® Technology
8.6.6. Agreements / Collaborations
8.7. PLEX™ Platform (PolyPid)
8.7.1. Overview
8.7.2. Financial Information
8.7.3. Technology and Mechanism of Action
8.7.4. Advantages of the Technology
8.7.5. Pipeline Drugs Using PLEX™
8.7.6. Agreements / Collaborations
8.8. Tethadur (pSivida)
8.8.1. Overview
8.8.2. Financial Performance
8.8.3. Technology and Mechanism of Action
8.8.4. Agreements / Collaborations
8.9. Phylomer® Peptides (Phylogica)
8.9.1. Overview
8.9.2. Financial Performance
8.9.3. Technology and Mechanism of Action
8.9.4. Agreements / Collaborations
8.11. Transcend Technology (biOasis)
8.11.1. Overview
8.11.2. Financial Performance
8.11.3. Technology and Mechanism of Action
8.11.4. Advantages of the Technology
8.11.5. Pipeline Drugs Using Transcend
8.11.6. Recent Developments
8.11.7. Agreements / Collaborations
8.12. LRP Technology (Angiochem)
8.12.1. Overview
8.12.2. Financial Performance
8.12.3. Technology and Mechanism of Action
8.12.4. Pipeline Drugs Using LRP Technology
8.12.5. Agreements / Collaborations
9. RECENT PARTNERSHIPS/COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models/Agreements
9.2.1. Product Development and Commercialisation
9.2.2. Technology Licensing
9.2.3. Research Collaborations
9.2.4. Technology Evaluation
9.2.5. Product Licensing
9.2.6. Manufacturing and Supply
9.2.7. Clinical Trial Collaborations
9.2.8. Other Agreements
9.3. Collaborations Amongst the Stakeholders has Steadied
9.4. Product Development and Technology Licensing are Preferred Modes of Partnership
10. VENTURE CAPITAL INTEREST
10.1. Chapter Overview
10.2. Instances of Funding for Focused on Formulation and Delivery of Biotherapeutics
10.3. Rising Venture Capital Interest
10.4. Funding Instances: Distribution by Type of Funding
10.5. Leading Technology Developers: Distribution by Number of Funding Instances
10.6. Most Active VC Firms/Institutions
11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Overall Drug Delivery Technologies Market, 2015-2025
11.4. Subcutaneous Drug Delivery Technologies Market, 2015-2025
11.5. Oral Drug Delivery Technologies Market, 2015-2025
11.6. Transdermal Drug Delivery Technologies Market, 2015-2025
11.7. Other Drug Delivery Technologies Market, 2015-2025
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
13. INTERVIEW TRANSCRIPTS
13.1. Interview Transcript I: Dr. Paul Ashton, President and CEO, pSivida
13.2. Interview Transcript II: Tom Saylor, Non-Executive Director, Arecor
13.3. Interview Transcript III: Xavier Rivero, Chief Operating Officer, Sagetis Biotech
13.4. Interview Transcript IV: Rob Hutchison, biOasis, CEO & Chairman
13.5. Interview Transcript V: Quinton Oswald, President and CEO, Neurotech Pharmaceuticals
14. CONCLUSION
14.1. Growing Interest Across Several Stakeholders
14.2. Multiple Drivers to Sustain Growth Momentum
14.3. Market for Formulation and Delivery Technologies to Grow at a Healthy Rate
14.4. Emergence of New Technologies
14.5. Concluding Remarks
LIST OF FIGURES
Figure 3.1 Classifications of Proteins
Figure 3.2 Approved Antibody Therapies: Distribution by Year of Approval
Figure 3.3 Approved Antibody Therapies: Distribution by Route of Administration
Figure 3.4 Different Types of Drug Delivery Technologies
Figure 3.5 Advantages of Novel Drug Delivery Technologies
Figure 4.1 Classification of Formulation and Delivery Technologies
Figure 4.2 Formulation and Delivery Technologies: Distribution by Type of Technology
Figure 4.3 Formulation and Delivery Technologies: Distribution by Focus of Technology
Figure 4.4 Formulation and Delivery Technologies: Distribution by Route of Administration
Figure 5.1 Oral Formulation and Drug Delivery Technologies Partnerships: Distribution by Type of Agreement
Figure 5.2 Merrion Pharmaceuticals: Revenues, 2012-HY2015 (USD Million)
Figure 5.3 Merrion Pharmaceuticals: Funding Instances (USD Million)
Figure 5.4 Multifunctional Role of Absorption Enhancer in GIPET®
Figure 5.5 Oramed: Funding Instances (USD Million)
Figure 5.6 Cosmo Pharmaceuticals: Revenues, 2012-HY2015 (EUR Million)
Figure 5.7 MMX® Technology Platform
Figure 5.8 Emisphere Technologies: Funding Instances (USD Million)
Figure 5.9 Generex Biotechnology™: Funding Instances (USD Million)
Figure 6.1 Subcutaneous Formulation and Drug Delivery Technologies: Distribution by Type of Agreement
Figure 6.2 Halozyme: Revenues, 2012-HY2015 (USD Million)
Figure 6.3 Halozyme Therapeutics: Funding Instances (USD Million)
Figure 6.4 BEPO™ Technology: Mechanism
Figure 6.5 Flamel Technologies: Revenues, 2012-2014 (USD Million)
Figure 6.6 Medusa™ Formulation Technology: Process
Figure 6.7 Xeris Pharmaceuticals: Funding Instances (USD Million)
Figure 6.8 XeriJect™ Technology: Process
Figure 6.9 Adocia: Revenues, 2012-HY2015 (EUR Million)
Figure 6.10 Adocia: Funding Instances (USD Million)
Figure 6.11 Ascendis Pharma: Funding Instances (USD Million)
Figure 7.1 Dermal Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
Figure 7.2 Corium: Revenues, 2012-HY2015 (USD Million)
Figure 7.3 Zosano Pharma: Revenues, 2013-2014 (USD Million)
Figure 7.4 Zosano Pharma: Funding Instances
Figure 8.1 Other Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
Figure 8.2 MonoSol Rx: Funding Instances (USD Million)
Figure 8.3 PolyPid: Funding Instances (USD Million)
Figure 8.4 pSivida: Revenues, 2012-HY2015 (USD Million)
Figure 8.5 biOasis: Funding Instances (USD Million)
Figure 8.6 Angiochem: Funding Instances (USD Million)
Figure 9.1 Product Development/Product Development and Commercialisation Agreements: Distribution by Focus of Technology
Figure 9.2 Technology Licensing Agreements: Distribution by Focus of Technology
Figure 9.3 Research Collaboration Agreements: Distribution by Focus of Technology
Figure 9.4 Technology Evaluation Agreements: Distribution by Focus of Technology
Figure 9.5 Product Licensing Agreements: Distribution by Focus of Technology
Figure 9.6 Manufacturing and Supply Agreements: Distribution by Focus of Technology
Figure 9.7 Clinical Trial Collaborations: Distribution by Focus of Technology
Figure 9.8 Other Agreements: Distribution by Focus of Technology
Figure 9.9 Delivery in Biotherapeutics: Year Wise Distribution of Partnership Instances
Figure 9.10 Collaborations: Most Active Companies
Figure 9.11 Collaborations: Distribution by Type of Partnership
Figure 10.1 Funding: Cumulative Number of Investments by Year, 1998-2015
Figure 10.2 Funding Instances: Distribution by Type of Funding, 1998-2015
Figure 10.3 Funding Instances: Distribution by Total Amount Invested, 1998-2015
Figure 10.4 Most Active Players: Evaluation by Number of Funding Instances, 1998-2015
Figure 10.5 Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)
Figure 10.6 Most Active VC Firms: Evaluation by Number of Funding Instances
Figure 11.1 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
Figure 11.2 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Figure 11.3 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
Figure 11.4 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Figure 11.5 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
Figure 11.6 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Figure 11.7 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
Figure 11.8 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Figure 11.9 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Base Scenario (USD Billion)
Figure 11.10 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Figure 14.1 Overall Biotherapeutics Formulation and Delivery Technologies Market: Comparative Evolution Scenarios, 2015, 2020 and 2025 (USD Billion) 
LIST OF TABLES
Table 3.1 Difference between Small Molecule Drugs and Biologics
Table 3.2 List of Approved Antibody Therapies
Table 4.1 List of Formulation and Delivery Technologies
Table 5.1 Merrion Pharmaceuticals: `Patent Portfolio
Table 5.2 GIPET® Platforms
Table 5.3 GIPET®: Pipeline of Drugs
Table 5.4 Merrion Pharmaceuticals: Licensing/Technology Evaluation Agreements
Table 5.5 POD™: Patent Portfolio
Table 5.6 POD™: Pipeline of Drugs
Table 5.7 Oramed: Relevant Agreements / Collaborations
Table 5.8 Cosmo Pharmaceuticals: Patent Portfolio
Table 5.9 MMX® Technology: Pipeline of Drugs
Table 5.10 Cosmo Pharmaceuticals: Relevant Agreements / Collaborations
Table 5.11 Eligen®: Pipeline of Drugs
Table 5.12 Emisphere Technologies: Relevant Agreements / Collaborations
Table 5.13 RapidMist: Pipeline of Drugs
Table 5.14 Generex Biotechnology: Technology Licensing/Evaluation Agreements
Table 5.15 Axcess Patent Family
Table 5.16 Axcess™: Pipeline of Drugs
Table 6.1 Enhanze™: Pipeline of Drugs
Table 6.2 Halozyme: Technology Licensing/Evaluation Agreements
Table 6.3 MedinCell: Patent Portfolio
Table 6.4 Medusa™: Pipeline of Drugs
Table 6.5 XeriJect™: Pipeline of Drugs
Table 6.6 BioChaperone®: Pipeline of Drugs
Table 6.7 TransCon: Pipeline of Drugs
Table 7.1 MicroCor®: Pipeline of Drugs
Table 7.2 MicronJet Needle: Pipeline of Drugs
Table 7.3 NanoPass Technologies: Technology Licensing / Evaluation Agreements
Table 7.4 Zosano Pharma™: Product Portfolio
Table 7.5 Zosano Pharma: Relevant Agreements / Collaborations
Table 8.1 NeuroNano Pharma: Patent Portfolio
Table 8.2 ProLynx: Patent Portfolio
Table 8.3 ProLynx: Technology Licensing/Evaluation Agreements
Table 8.4 Aegis Therapeutics: Technology Licensing/Evaluation Agreements
Table 8.5 PharmFilm®: Pipeline of Drugs
Table 8.6 MonoSol Rx: Technology Licensing Evaluation Agreements
Table 8.7 PLEX: Pipeline of Drugs
Table 8.8 PolyPid: Relevant Agreements / Collaborations
Table 8.9 pSivida: Technology Licensing/Evaluation Agreements
Table 8.10 Phylogica: Technology Licensing/Evaluation Agreements
Table 8.11 biOasis: Pipeline
Table 8.12 biOasis Technologies: Technology Licensing/Evaluation Agreements
Table 8.13 LRP Technology: Pipeline of Drugs
Table 8.14 Angiochem: Technology Licensing/Evaluation Agreements
Table 9.1 Product Development/Product Development and Commercialisation Agreements, 2005 Onwards
Table 9.2 Technology Licensing Agreements, 2005 Onwards
Table 9.3 Research Collaboration Agreements, 2005 Onwards
Table 9.4 Technology Evaluation Agreements, 2005 Onwards
Table 9.5 Product Licensing Agreements, 2005 Onwards
Table 9.6 Manufacturing and Supply Agreements, 2005 Onwards
Table 9.7 Clinical Trial Collaborations, 2005 Onwards
Table 9.8 Other Agreements
Table 10.1 List of Funding Instances and Investors Involved
Table 10.2 Types of Funding Instances, 1998- 2015
Table 12.1 SWOT Analysis
Table 15.1 Approved Antibody Therapies: Distribution by Year of Approval
Table 15.2 Approved Antibody Therapies: Distribution by Route of Administration
Table 15.3 Formulation and Delivery Technologies: Distribution by Type of Technology
Table 15.4 Formulation and Delivery Technologies: Distribution based on Focus of Technology
Table 15.5 Formulation and Delivery Technologies: Distribution by Route of Administration
Table 15.6 Oral Formulation and Drug Delivery Technology Partnerships: Distribution by Type of Agreement
Table 15.7 Merrion Pharmaceuticals: Revenues, 2012-HY2015 (USD Million)
Table 15.8 Merrion Pharmaceuticals: Funding Instances (USD Million)
Table 15.9 Oramed: Funding Instances (USD Million)
Table 15.10 Cosmo Pharmaceuticals: Revenues, 2012-HY2015 (EUR Million)
Table 15.11 Emisphere Technologies: Funding Instances (USD Million)
Table 15.12 Generex Biotechnology™: Funding Instances (USD Million)
Table 15.13 Subcutaneous Formulation and Drug Delivery Technologies: Distribution by Type of Agreement
Table 15.14 Halozyme: Revenues, 2012-HY2015 (USD Million)
Table 15.15 Halozyme Therapeutics: Funding Instances (USD Million)
Table 15.16 Flamel Technologies: Revenues, 2012-2014 (USD Million)
Table 15.17 Xeris Pharmaceuticals: Funding Instances (USD Million)
Table 15.18 Adocia: Revenues, 2012-HY2015 (EUR Million)
Table 15.19 Adocia: Funding Instances (USD Million)
Table 15.20 Ascendis Pharma: Funding Instances (USD Million)
Table 15.21 Dermal Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
Table 15.22 Corium: Revenues, 2012-HY2015 (USD Million)
Table 15.23 Zosano Pharma: Revenues, 2013-2014 (USD Million)
Table 15.24 Zosano Pharma: Funding Instances
Table 15.25 Other Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
Table 15.26 MonoSol Rx: Funding Instances (USD Million)
Table 15.27 PolyPid: Funding Instances (USD Million)
Table 15.28 pSivida: Revenues, 2012-HY2015 (USD Million)
Table 15.29 biOasis: Funding Instances (USD Million)
Table 15.30 Angiochem: Funding Instances (USD Million)
Table 15.31 Product Development and Commercialisation Agreements: Distribution by Focus of Technology
Table 15.32 Technology Licensing Agreements: Distribution by Focus of Technology
Table 15.33 Research Collaboration Agreements: Distribution by Focus of Technology
Table 15.34 Technology Evaluation Agreements: Distribution by Focus of Technology
Table 15.35 Product Licensing Agreements: Distribution by Focus of Technology
Table 15.36 Manufacturing and Supply Agreements: Distribution by Focus of Technology
Table 15.37 Clinical Trial Collaborations: Distribution by Focus of Technology
Table 15.38 Other Agreements: Distribution by Focus of Technology
Table 15.39 Delivery in Biotherapeutics: Year Wise Distribution of Partnership Instances
Table 15.40 Collaborations: Distribution by Type of Partnership
Table 15.41 Funding: Cumulative Number of Investments by Year, 1998-2015
Table 15.42 Funding Instances: Distrinutoi by Type of Funding, 1998-2015
Table 15.43 Funding Instances: Distribution by Total Amount Invested, 1998-2015
Table 15.44 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
Table 15.45 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
Table 15.46 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
Table 15.47 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
Table 15.48 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Table 15.49 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
Table 15.50 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
Table 15.51 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
Table 15.52 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
Table 15.53 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
Table 15.54 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Table 15.55 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
Table 15.56 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
Table 15.57 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
Table 15.58 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
Table 15.59 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
Table 15.60 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Table 15.61 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
Table 15.62 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
Table 15.63 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
Table 15.64 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
Table 15.65 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
Table 15.66 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Table 15.67 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
Table 15.68 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Conservative Scenario (USD Billion)
Table 15.69 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Base Scenario (USD Billion)
Table 15.70 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Optimistic Scenario (USD Billion)
Table 15.71 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
Table 15.72 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
Table 15.73 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
Table 15.74 Overall Biotherapeutics Formulation and Delivery Technologies Market: Comparative Evolution Scenarios, 2015, 2020 and 2025 (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report